| Autor: |
de Haas, Masja, Thurik, Florentine F, van der Ploeg, Catharina P B, Veldhuisen, Barbera, Hirschberg, Hoang, Soussan, Aicha Ait, Woortmeijer, Heleen, Abbink, Frithjofna, Page-Christiaens, Godelieve C M L, Scheffer, Peter G, Ellen van der Schoot, C |
| Zdroj: |
BMJ (British Medical Journal); 2016, Vol. 355 Issue: 11 pi5789-i5789, 1p |
| Abstrakt: |
Objective To determine the accuracy of non-invasive fetal testing for the RHDgene in week 27 of pregnancy as part of an antenatal screening programme to restrict anti-D immunoglobulin use to women carrying a child positive for RHD.Design Prospectively monitoring of fetal RHDtesting accuracy compared with serological cord blood typing on introduction of the test. Fetal RHDtesting was performed with a duplex real time quantitative polymerase chain reaction, with cell-free fetal DNA isolated from 1 mL of maternal plasma The study period was between 4 July 2011 and 7 October 2012. The proportion of women participating in screening was determined.Setting Nationwide screening programme, the Netherlands. Tests are performed in a centralised setting.Participants 25 789 RhD negative pregnant women.Main outcome measures Sensitivity, specificity, false negative rate, and false positive rate of fetal RHDtesting compared with serological cord blood typing; proportion of technical failures; and compliance to the screening programme.Results A fetal RHDtest result and serological cord blood result were available for 25 789 pregnancies. Sensitivity for detection of fetal RHDwas 99.94% (95% confidence interval 99.89% to 99.97%) and specificity was 97.74% (97.43% to 98.02%). Nine false negative results for fetal RHDtesting were registered (0.03%, 95% confidence interval 0.01% to 0.06%). In two cases these were due to technical failures. False positive fetal RHDtesting results were registered for 225 samples (0.87%, 0.76% to 0.99%). Weak RhD expression was shown in 22 of these cases, justifying anti-D immunoglobulin use. The negative and positive predictive values were 99.91% (95% confidence interval 99.82% to 99.95%) and 98.60% (98.40% to 98.77%), respectively. More than 98% of the women participated in the screening programme.Conclusions Fetal RHDtesting in week 27 of pregnancy as part of a national antenatal screening programme is highly reliable and can be used to target both antenatal and postnatal anti-D immunoglobulin use. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
